Therapies in early development for the treatment of urinary tract inflammation

References

• Lee G, Romih R, Zupancic D. Cystitis: from urothelial cell biology to clinical applications. Biomed Res Int. 2014;2014:473536.
   PubMedGoogle Scholar
• Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect Inst Pasteur. 2003;5:449–456.
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
   PubMed Web of Science ®Google Scholar
• Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653–660.
   PubMed Web of Science ®Google Scholar
• Foxman B, Gillespie B, Koopman J, et al. Risk factors for secondary urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194–1205.
   PubMed Web of Science ®Google Scholar
• Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(Suppl 2):S32S47.
   Google Scholar
• Laupland KB, Ross T, Pitout JD, et al. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35:150–153.
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Stapleton AE. Urinary tract infection pathogenesis: host factors. Infect Dis Clin North Am. 2014;28(1):149–159.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36(3):616–648.
   PubMed Web of Science ®Google Scholar
• Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol. 2010;8(1):26–38.
   PubMed Web of Science ®Google Scholar
• Lüthje P, Brauner A. Virulence factors of uropathogenic E. coli and their interaction with the host. Adv Microb Physiol. 2014;65:337–372.
   PubMed Web of Science ®Google Scholar
• Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991;4(1):80–128.
   PubMed Web of Science ®Google Scholar
• Kurtaran B, Candevir A, Tasova Y, et al. Antibiotic resistance in community-acquired urinary tract infections: prevalence and risk factors. Med Sci Monit. 2010;16:CR246C251.
   Google Scholar
• Sjöberg I, Grahn E, Håkansson S, et al. Influence of phenoxymethylpenicillin on the vaginal ecosystem. Gynecol Obstet Invest. 1992;33(1):42–46.
   PubMed Web of Science ®Google Scholar
• Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1(2):101–114.
   PubMedGoogle Scholar
• Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PloS Biol. 2008;6:e280.
   PubMed Web of Science ®Google Scholar
• Foxman B, Buxton M. Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women. Curr Infect Dis Rep. 2013;15(2):124–129.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network(EARS-Net). 2012. [cited 2015 Nov 14]. Available from: www.ecdc.europa.eu/en/publications/Publications/antimicrobial resistance-surveillance-europe-2012.pdf
   Google Scholar
• Edelsberg J, Weycker D, Barron R, et al. Prevalence of antibiotic resistance in US hospital. Diagn Microbiol Infect Dis. 2014;78:255–262.
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Perletti G,ME, et al. Finafloxacin for the treatment of urinary tract infections. Expert Opin Investig Drug. 2015;24(7):957–963.
   PubMed Web of Science ®Google Scholar
• Stubbings W, Leow P, Yong GC, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluorquinolone, under standard and acidic conditions. Antimicrob Agents Chemother. 2011;55:4394–4397.
   PubMed Web of Science ®Google Scholar
• Muller MT, Stubbings W, Vente A. Comparative activity between finafloxacin (FIN) and other fluoroquinolones against bacterial and eukaryotic type II topoisomerases (Abstract F1-2046). 48th ICAAC/46th IDSA; 2008; Washington DC.
   Google Scholar
• Idelevich EA, Krigeskorte A, Stubbings W, et al. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes. J Antimicrob Chemother. 2011;66:2809–2813.
   PubMed Web of Science ®Google Scholar
• Genzel GH, Stubbings W, Stingu CS, et al. Activity of the investigational fluorquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria. Int J Antimicrob Agents. 2014;44:420–423.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Van Bambeke F, Tulkens PM. Activity of finafloxacin, a novel fluorquinolone with increased activity at acidic pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophilal. Int J Antimicrob Agents. 2011;38:52–59.
   PubMed Web of Science ®Google Scholar
• Luckermann M, Mooney L, Patel H, et al. A phase I study to determine safety, tolerability and pharmacokinetics (PK) of intravenous doses of finafloxacin HCl (FIN) in healthy subjects (A-1960). 52nd ICAAC 2012; 2012; S. Francisco USA.
   Google Scholar
• New Drugs Online Database. [cited 2015 Nov 20]. Available from: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6498
   Google Scholar
• Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of siderophore cephalosporin S-649266 against Enterobacteriaceae clinical isolates including carbapenem-resistant strains. Antimicrob Agents Chemother. 2015 Nov 16. ;60(2):729–734.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [cited 2015 Nov 20]. Available from: www.clinicaltrials.gov/ct2/show/NCT02321800
   Google Scholar
• Billips BK, Schaeffer AJ, Klumpp DJ. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect Immun. 2008;76(9):3891–3900.
   PubMed Web of Science ®Google Scholar
• Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(6):663–676.
   PubMed Web of Science ®Google Scholar
• Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7(8):430–441.
   PubMed Web of Science ®Google Scholar
• Shetty AV, Kumar SH, Shekar M, et al. Prevalence of adhesive genes among uropathogenic Escherichia coli strains isolated from patients with urinary tract infections in Mangalore. Indian J Med Microbiol. 2014;32:175–178.
   PubMed Web of Science ®Google Scholar
• Ripper-Lampe KE, Lang M, Ceri H, et al. Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatis model. Infect Immun. 2001;69(10):6515–6519.
   PubMed Web of Science ®Google Scholar
• Smith YC, Rasmussen SB, Grande KK, et al. Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice. Infect Immun. 2008;76(7):2978–2990.
   PubMed Web of Science ®Google Scholar
• Uhlén P, Laestadius A, Jahnukainen T, et al. Alpha-haemolysin of uropathogenic E. coli induces Ca2+ oscillations in renal epithelial cells. Nature. 2000;405(6787):694–697.
   PubMed Web of Science ®Google Scholar
• O’Hanley P, Lalonde G, Ji G. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun. 1991;59(3):1153–1161.
   PubMed Web of Science ®Google Scholar
• Knust Z, Schmidt G. Cytotoxic necrotizing factors (CNFs) – a growing toxin family. Toxins. 2010;2:116–127.
   PubMed Web of Science ®Google Scholar
• Villalonga P, Ridley A. Rho GTPases and cell cycle control. Growth Factors. 2006;24:159–164.
   PubMed Web of Science ®Google Scholar
• Mills M, Meysick KC, O’Brien AD. Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism. Infect Immun. 2000;68:5869–5880.
   PubMed Web of Science ®Google Scholar
• Rippere-Lampe KE, O’Brien AD, Conran R, et al. Mutation of the gene encoding cytotoxic necrotizing factor type 1 (CNF1) attenuates the virulence of uropathogenic Escherichia coli. Infect Immun. 2001;69:3954–3964.
   PubMed Web of Science ®Google Scholar
• Smith MA, Weingarten RA, Russo LM, et al. Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli. Infect Immun. 2015;83(4):1661–1673.
   PubMed Web of Science ®Google Scholar
• Zhang A-S, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem. 2009;284(2):711–715.
   PubMed Web of Science ®Google Scholar
• Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol. 2009;21(1):63–67.
   PubMed Web of Science ®Google Scholar
• Torres AG, Redford P, Welch RA, et al. TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence on the mouse. Infect Immun. 2001;69(10):6179–6185.
   PubMed Web of Science ®Google Scholar
• Hagan EC, Llpyd AL, Rasko DA, et al. Escherichia coli global gene expression in urine from women with urinary tract infection. PloS Pathog. 2010;6(11):e1001187.
   PubMed Web of Science ®Google Scholar
• Watts RE, Totsika M, Challinor VL, et al. Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli. Infect Imun. 2012;80:333–344.
   PubMed Web of Science ®Google Scholar
• Henderson JP, Crowley JR, Pinker JS, et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathogen. 2009;5(2):e10000305.
   Web of Science ®Google Scholar
• Alteri CJ, Hagan EC, Sivick KE, et al. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PloS Pathogen. 2009;5(9):e10000586.
   Web of Science ®Google Scholar
• Brumbaugh AR, Smith SN, Mobley HL. Immunization with the yersiniabatin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect Immun. 2013;81:3309–3316.
   PubMed Web of Science ®Google Scholar
• Cross A, Artenstein A, Que J, et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis. 1994;170(4):834–840.
   PubMed Web of Science ®Google Scholar
• Miajlovic H, Smith SG. Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol Lett. 2014;354(1):1–9.
   PubMed Web of Science ®Google Scholar
• Whitfield C, Roberts IS. Structure, assembly, and regulation of expression of capsules in Escherichia coli. Mol Microbiol. 1999;31(5):1307–1319.
   PubMed Web of Science ®Google Scholar
• Jann K, Jann B. Polysaccharide antigens of Escherichia coli. Rev Infect Dis. 1987;9(Suppl 5):S517S526.
   Google Scholar
• Feldman MF, Wacker M, Hernandez M, et al. Engineering N-linked protein glycosylation wwith diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad USA. 2005;102(8):3016–3021.
   PubMed Web of Science ®Google Scholar
• Ihssen J, Kowarik M, Dilettoso S, et al. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010;9:61.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Wacker M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progess in the field. J Infect Dis. 2015;pii:jiv429. [Epub ahead of print].
   Google Scholar
• ClinicalTrials.gov. [cited 2015 Nov 20]. Available from: www.clinicaltrials.gov/ct2/show/NCT02289794
   Google Scholar
• Sabharwal N, Chibber S, Harjal K. New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvant flaggelin “b” induced immunty. Immunol Lett. 2014;162(2Pt B):229–238.
   PubMed Web of Science ®Google Scholar
• Mittal R, Aggarwal S, Sharma S, et al. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health. 2009;2:101–111.
   PubMedGoogle Scholar
• Winstanley C, Coulson MA, Wepner B, et al. Hart CA Flagellin gene and protein variation amongst clinical isolates of Pseudomonas aeruginosa. Microbiology. 1996;142:2145–2151.
   PubMed Web of Science ®Google Scholar
• Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flaggelin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001;167:1882–1885.
   PubMed Web of Science ®Google Scholar
• Rafsanjany N, Lechtenberg M, Petereit F, et al. Antiadhesion as a functional concept for protection against uropathogenic Escherichia coli: in vitro studies with traditionally used plants with antiadhesive activity against uropathogenic Escherichia coli. J Ethnopharmacol. 2013;145(2):591–597.
   PubMed Web of Science ®Google Scholar
• Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;10:CD001321.
   PubMed Web of Science ®Google Scholar
• Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007;51(6):732–737.
   PubMed Web of Science ®Google Scholar
• Howell AB, Reed JD, Krueger CG, et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry. 2005;66(18):2281–2291.
   PubMed Web of Science ®Google Scholar
• Martinez JJ, Mulvey MA, Schilling JD, et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. Embo J. 2000;19:2803–2812.
   PubMed Web of Science ®Google Scholar
• Chen SL, Hung CS, Pinkner JS, et al. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci USA. 2009;106(52):22439–22444.
   PubMed Web of Science ®Google Scholar
• Asadi Karam MR, Oloomi M, Mahdavi M, et al. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine. 2013;31:1210–1216.
   PubMed Web of Science ®Google Scholar
• Langermann S, Möllby R, Burlein JE, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis. 2000;181(2):774–778.
   PubMed Web of Science ®Google Scholar
• Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276(5312):607–611.
   PubMed Web of Science ®Google Scholar
• Armbruster CE, Mobley HL. Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol. 2012;10(11):743–754.
   PubMed Web of Science ®Google Scholar
• Wazait HD, Patel HR, Veer V, et al. Catheter-associated urinary tract infections: prevalence of uropathogens and pattern of antimicrobial resistance in a UK hospital (1996-2001). BJU Int. 2003;91(9):806–809.
   PubMed Web of Science ®Google Scholar
• Jansen AM, Lockatell V, Johnson DE, et al. Mannose-resistant proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria and contribute to biofilm formation. Infect Immun. 2004;72:7294–7305.
   PubMed Web of Science ®Google Scholar
• Habibi M, Asadi Karam MR, Bouzari S. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model. Int Immunopharmacol. 2015;28(1):70–78.
   PubMed Web of Science ®Google Scholar
• Habibi M, Asadi Karam MR, Shokrgozar MA, et al. Intranasal immunization with fusion protein MrpH-FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Mol Immunol. 2015;64(2):285–294.
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Pinkner JS, Caparon MG, et al. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci Transl Med. 2014;6(254):254ra127.
   PubMed Web of Science ®Google Scholar
• Nallapareddy SR, Singh KV, Sillanpää J, et al. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest. 2006;116:2799–2807.
   PubMed Web of Science ®Google Scholar
• Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79–84.
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349–1353.
   PubMed Web of Science ®Google Scholar
• Bauer HW, Alloussi S, Egger G, et al. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542–548.
   PubMed Web of Science ®Google Scholar
• Marinova S, Nenkov P, Markova R, et al. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int J Immunopathol Pharmacol. 2005;18(3):457–473.
   PubMed Web of Science ®Google Scholar
• Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol. 2005;55(2):441–455.
   PubMed Web of Science ®Google Scholar
• Totsika M, Kostakioti M, Hannan TJ. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis. 2013;208(6):921–928.
   PubMed Web of Science ®Google Scholar
• Klein T, Abgottspon D, Wittwer M, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010;53:8627–8641.
   PubMed Web of Science ®Google Scholar
• Cusumano CK, Pinker JS, Han Z, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3(109):109ra115.
   PubMed Web of Science ®Google Scholar
• King SS, Young DA, Nequin LG, et al. Use of specific sugars to inhibit bacterial adherence to equine endometrium in in vitro. Am J Vet Res. 2000;61(4):446–449.
   PubMed Web of Science ®Google Scholar
• Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12(1):3–10.
   PubMed Web of Science ®Google Scholar
• Pazin C, De Souza Mitidieri AM, Silva AP, et al. Treatment of bladder pain syndrome and interstitial cystitis: a systematic review. Int Urogynecol J. 2015 Aug 14. [Epub ahead of print].
   PubMedGoogle Scholar
• Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004;93(9):1262–1266.
   PubMed Web of Science ®Google Scholar
• Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet. 2007;96(3):192–195.
   PubMed Web of Science ®Google Scholar
• Lee DG, Cho JJ, Park HK, et al. Preventive effects of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology. 2010;75(4):949–954.
   PubMed Web of Science ®Google Scholar
• Yildiz N, Alpay H, Tugtepe H, et al. Intravesical hyaluronic acid treatment improves bacterial cystitis and reduces cystitis-induced hypercontractility in rats. Int J Urol. 2015;22(6):598–603.
   PubMed Web of Science ®Google Scholar
• Kirjavainen PV, Pautler S, Baroja ML, et al. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin Vaccine Immunol. 2009;16(1):29–36.
   PubMed Web of Science ®Google Scholar
• Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212–1217.
   PubMed Web of Science ®Google Scholar
• Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015 Dec 23;12:CD008772.
   PubMed Web of Science ®Google Scholar
• Duell BL, Carey AJ, Tan CK, et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol. 2012;188(2):781–792.
   PubMed Web of Science ®Google Scholar
• Schiwon M, Weisheit C, Franken L, et al. Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium. Cell. 2014;156(3):456–468.
   PubMed Web of Science ®Google Scholar
• Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis. 2004;36(4):296–301.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Mysorekar IU, Hung CS, et al. Early severe inflammatory responses to uropathogenic E.coli predispose to chronic and recurrent urinary tract infection. PloS Pathog. 2010;6(8):e1001042.
   PubMed Web of Science ®Google Scholar
• Schlager TA, LeGallo R, Innes D, et al. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol. 2011;186(6):2359–2364.
   PubMed Web of Science ®Google Scholar
• Chen TC, Tsai JP, Huang HJ, et al. Regulation of cyclooxygenase-2 expression in human bladder epithelial cells infected with type I fimbriated uropathogenic E. coli.Cell Microbiol. 2011;13(11):1703–1713.
   PubMed Web of Science ®Google Scholar
• Wheeler MA, Hausladen DA, Yoon JH, et al. Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol. 2002;168(4 Pt 1):1568–1573.
   PubMed Web of Science ®Google Scholar
• de Jongh R, Grol S, van Koeveringe GA, et al. The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall. J Cell Mol Med. 2009;13(9B):3069–3081.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Roberts PL, Riehl TE, et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EbioMedicine. 2014;1(1):46–57.
   PubMed Web of Science ®Google Scholar
• Bleidorn J, Gágyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?–results of a randomized controlled pilot trial. BMC Med. 2010;8:30.
   PubMed Web of Science ®Google Scholar
• Kalle AM, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother. 2011;55(1):439–442.
   PubMed Web of Science ®Google Scholar
• Konkol Y, Bernoulli J, Streng T, et al. Intravesical treatment with cis-urocanic acid improves bladder function in rat model of acute bladder inflammation. Neurourol Urodyn. 2015 Jul 14. doi:10.1002/nau.22818. [Epub ahead of print].
   PubMedGoogle Scholar
• Arentsen HC, Jansen CF, Hulsbergen-Van De Kaa CA, et al. Antitumor effects of cis-urocanic acid on experimental urothelial cell carcinoma of the bladder. J Urol. 2012;187(4):1445–1449.
   PubMed Web of Science ®Google Scholar
• Peuhu E, Kaunisto A, Laihia JK, et al. Molecular targets for the protodynamic action of cis-urocanic acid in human bladder carcinoma cells. BMC Cancer. 2010;19:521.
   Web of Science ®Google Scholar
• Viiri J, Jauhonen HM, Kauppinen A, et al. Cis-urocanic acid suppresses UV-B induced interleukin-6 and −8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Mol Vis. 2009;15:1799–1805.
   PubMed Web of Science ®Google Scholar
• Bannerman DD, Rinaldi M, Vinyard BT, et al. Effects of intramammary infusion of cis-urocanic acid on mastitis-associated inflammation and tissue injury in dairy cows. Am J Vet Res. 2009;70(3):373–382.
   PubMed Web of Science ®Google Scholar
• Bae W-J, Ha U-S, Kim S, et al. Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystits. Neurourol Urodyn. 2015;34(1):86–91.
   PubMed Web of Science ®Google Scholar
• Cooper R, Morré DJ, Morré DM. Medicinal benefits of green tea: part I. Review of noncancer health benefits. J Altern Complement Med. 2005;11(3):521–528.
   PubMed Web of Science ®Google Scholar
• Cooper R, Morré DJ, Morrè DM. Medicinal benefits of green tea: part II. Review of anticancer properties. J Altern Complement Med. 2005;11(4):639–652.
   PubMed Web of Science ®Google Scholar
• Reygaert W, Jusufi I. Green tea as an effective antimicrobial for urinary tract infections caused by Escherichia coli. Front Microbiol. 2013;4:162.
   PubMed Web of Science ®Google Scholar
• Noormandi A, Dabaghzadeh F. Effects of gree tea on Escherichia coli as uropathogen. J Tradit Complement Med. 2014;5(1):15–20.
   PubMedGoogle Scholar
• Rosenberg S, Horowitz R, Coppenhagen-Glazer S, et al. Intravesical administration of green tea extract attenuates the inflammatory response of bacterial cystitis-a rat model. MJU Int. 2014;114(4):601–607.
   Google Scholar
• Harrington DA, Sharma AK, Erickson BA, et al. Bladder tissue engineering through nanotechnology. World J Urol. 2008;26(4):315–322.
   PubMed Web of Science ®Google Scholar
• Mukherjee B. Nanosize drug delivery system. Curr Pharm Niotechnol. 2013;14(15):1221.
   PubMed Web of Science ®Google Scholar
• Labbaf S, Horsley H, Chang MW, et al. An encapsulated drug delivery system for recalcitrant urinary tract infection. J R Soc Interface. 2013;10(89):20130747.
   PubMed Web of Science ®Google Scholar
• Labbaf S, Ghanbar H, Stride E, et al. Preparation of multilayered polymeric structures using a novel four-needle coaxial electrohydrodynamic device. Macromol Rapid Commun. 2014;35(6):618–623.
   PubMed Web of Science ®Google Scholar
• Abbasi F, Mirzadeh H, Kaybab A. Modification of polysiloxane polymers for biomedical applications: a review. Polym Int. 2001;50:1279–1287.
   Web of Science ®Google Scholar
• Boots AW, Wilms LC, Swennen EL, et al. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition. 2008;24(78):703–710.
   PubMed Web of Science ®Google Scholar
• Garcia-mediavilla V, Crespo I, Collado PS, et al. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007;557(23):221–229.
   PubMed Web of Science ®Google Scholar
• Wang BL, Gao X, Men K, et al. Treating acute cystitis with biodegradable micelle-encapsulated quercetin. Int J Nanomedicine. 2012;7:2239–2247.
   PubMed Web of Science ®Google Scholar
• Liu S, Qiao S, Li L, et al. Surface charge-conversion polymeric nanoparticles for photodynamic treatment of urinary tract bacterial infections. Nanotechnology. 2015;26(49):495602.
   PubMed Web of Science ®Google Scholar
• Kostakioti M, Hultgren S, Hadjifrangiskou M. Molecular blueprint of uropathogenic Escherichia coli virulence provides clues toward the development of anti-virulence therapeutics. Virulence. 2012;3(7):592–594.
   PubMed Web of Science ®Google Scholar
• Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117–128.
   PubMed Web of Science ®Google Scholar
• Wieser A, Romann E, Magistro G, et al. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun. 2010;78(8):3432–3442.
   PubMed Web of Science ®Google Scholar
• Abraham SN, Miao Y. The nature of immune responses to urinary tract infections. Nat Rev Immunol. 2015;15(10):655–663.
   PubMed Web of Science ®Google Scholar
• Mobley HL, Alteri CJ. Development of a vaccine against Escherichia coli urinary tract infections. Pathogens. 2015 Dec 31;5(1):1.
   PubMedGoogle Scholar
• McLachlan JB, Shelburne CP, Hart JP, et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med. 2008;14(5):536–541.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC)/European Medicines Agency (EMEA). ECDC/EMEA joint technical report: the bacterial challenge: time to react. [cited 2015 Nov 20]. Available from www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
   Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109.
   PubMed Web of Science ®Google Scholar